Based on Long-Acting Leuprorelin
Results of phase III clinical trials of a drug for prostate cancer based on long-acting leuprorelin have been announced. The drug (FP-001 LMIS), developed by Foresee Pharmaceutical, is a suspension for injections based on synthetic analogue of gonadotropin-releasing hormone – leuproprelin. Leuproprelin-based products have been used for treatment of cancers since the 80-ies of the XXth century and require monthly administration.
Clinical trials, involving 137 males with progressive prostate carcinoma, who received the novel drug FP-001 LMIS at 50 mg once in half a year, had blood serum testosterone level decreased to ≤ 50 ng/dl in 132 subjects. No adverse effects were observed.